Change of glucometabolic activity per PSMA expression predicts survival in mCRPC patients non-responding to PSMA radioligand therapy: introducing a novel dual imaging biomarker

PurposeThe value of [18F]fluorodeoxyglucose ([18F]FDG) PET/CT in monitoring prostate-specific membrane antigen (PSMA) targeted radioligand therapy (RLT) is still unclear. The aim of this study was to identify appropriate prognostic dynamic parameters derived from baseline and follow-up [18F]FDG and...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Caroline Burgard, Jakob Engler, Arne Blickle, Mark Bartholomä, Stephan Maus, Andrea Schaefer-Schuler, Fadi Khreish, Samer Ezziddin, Florian Rosar
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Frontiers Media S.A. 2024-01-01
Цуврал:	Frontiers in Medicine
Нөхцлүүд:	PSMA—prostate-specific membrane antigen PET/CT radioligand therapy prostate cancer dual imaging
Онлайн хандалт:	https://www.frontiersin.org/articles/10.3389/fmed.2023.1339160/full
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!